

Accepted Manuscript

Title: Glycosimilarity assessment of biotherapeutics 1:
Quantitative comparison of the *N*-glycosylation of the
innovator and a biosimilar version of etanercept

Authors: Beata Borza, Marton Szigeti, Akos Szekrenyes,
Laszlo Hajba, Andras Guttman



PII: S0731-7085(18)30044-X
DOI: <https://doi.org/10.1016/j.jpba.2018.02.021>
Reference: PBA 11789

To appear in: *Journal of Pharmaceutical and Biomedical Analysis*

Received date: 5-1-2018
Revised date: 6-2-2018
Accepted date: 8-2-2018

Please cite this article as: Beata Borza, Marton Szigeti, Akos Szekrenyes, Laszlo Hajba, Andras Guttman, Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the *N*-glycosylation of the innovator and a biosimilar version of etanercept, *Journal of Pharmaceutical and Biomedical Analysis* <https://doi.org/10.1016/j.jpba.2018.02.021>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept

Beata Borza¹, Marton Szigeti¹, Akos Szekrenyes¹, Laszlo Hajba², Andras Guttman^{1,2*}

¹ Horváth Csaba Laboratory of Bioseparation Sciences, University of Debrecen, Hungary

² Research Institute for Biomolecular and Chemical Engineering, University of Pannonia, Veszprem, Hungary

Corresponding author: Andras Guttman, Horváth Csaba Laboratory of Bioseparation Sciences, University of Debrecen, Nagyerdei krt 98, Debrecen, Hungary 4032. Email: guttmanandras@med.unideb.hu

Highlights

- Glycosimilarity is introduced to quantitatively address N-glycosylation differences
- Practical examples of glycosimilarity assessment are given (innovator and biosimilar)
- Quantitative differences between the N-glycan profiles are discussed

Abstract

The carbohydrate moieties on the polypeptide chains in most glycoprotein based biotherapeutics and their biosimilars plays essential roles in such major mechanisms of actions as antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, anti-inflammatory functions and serum clearance. In addition, alteration in glycosylation may influence the safety and efficacy of the product. Glycosylation, therefore, is considered as one of the important critical quality attributes of glycoprotein biotherapeutics, and consequently for their biosimilar counterparts. Thus, the carbohydrate moieties of such biopharmaceuticals (both innovator and biosimilar products) should be closely scrutinized during all stages of the manufacturing process. In this paper we introduce a rapid, capillary gel electrophoresis based process to quantitatively assess the glycosylation aspect of biosimilarity (referred to as glycosimilarity) between the innovator and a biosimilar versions of etanercept (Enbrel[®] and Benepali[®], respectively), based on their N-linked carbohydrate profiles. Differences in sialylated, core fucosylated, galactosylated and high mannose glycans were all quantified. Since the mechanism of action of etanercept is

Download English Version:

<https://daneshyari.com/en/article/7626702>

Download Persian Version:

<https://daneshyari.com/article/7626702>

[Daneshyari.com](https://daneshyari.com)